MX2023014530A - Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. - Google Patents

Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.

Info

Publication number
MX2023014530A
MX2023014530A MX2023014530A MX2023014530A MX2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A MX 2023014530 A MX2023014530 A MX 2023014530A
Authority
MX
Mexico
Prior art keywords
nitroxoline
treatment
cutaneous neurofibroma
neurofibroma
cutaneous
Prior art date
Application number
MX2023014530A
Other languages
English (en)
Spanish (es)
Inventor
David Brown
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of MX2023014530A publication Critical patent/MX2023014530A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023014530A 2021-06-09 2022-06-09 Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. MX2023014530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (1)

Publication Number Publication Date
MX2023014530A true MX2023014530A (es) 2024-04-10

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014530A MX2023014530A (es) 2021-06-09 2022-06-09 Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.

Country Status (12)

Country Link
US (1) US20240261276A1 (https=)
EP (1) EP4351576A1 (https=)
JP (1) JP2024520690A (https=)
KR (1) KR20240024175A (https=)
CN (1) CN117769419A (https=)
AU (1) AU2022290019A1 (https=)
BR (1) BR112023025789A2 (https=)
CA (1) CA3221964A1 (https=)
GB (1) GB202108224D0 (https=)
IL (1) IL309177A (https=)
MX (1) MX2023014530A (https=)
WO (1) WO2022258972A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039822C (en) * 2016-10-14 2026-02-17 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same

Also Published As

Publication number Publication date
GB202108224D0 (en) 2021-07-21
CN117769419A (zh) 2024-03-26
CA3221964A1 (en) 2022-12-15
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
WO2022258972A1 (en) 2022-12-15
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
KR20240024175A (ko) 2024-02-23
US20240261276A1 (en) 2024-08-08
IL309177A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MY208632A (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2025009723A (es) Metodos de tratamiento contra adicciones
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
TW200806300A (en) New therapeutic combinations for the treatment of depression
GEAP202315801A (en) Antibacterial compounds
MY202884A (en) Compounds useful in hiv therapy
MX2024004725A (es) Metodos novedosos.
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
MX2023014530A (es) Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
MX2019006768A (es) Peptidos antimicrobianos.
MX2024006105A (es) Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12021550258A1 (en) Cdk8/19 inhibitors
MY205944A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2021005944A (es) Inhibidores de rip1.
MX2025006240A (es) Composicion farmaceutica para la prevencion o tratamiento contra ulcera peptica relacionada a farmacos, que comprende zastaprazan o una sal farmaceuticamente aceptable del mismo